Recent progress in sepsis epidemiology – have we learned enough? by Gerlach, Herwig & Keh, Didier
333 ICU = intensive care unit; SOAP = Sepsis Occurrence in the Acutely ill Patients study.
Available online http://ccforum.com/http://ccforum.com/content/7/5/333
It seems to be a good time for optimists. Within less than
24 months, three large randomized controlled trials [1–3]
were able to demonstrate that improvement in outcome in
patients with severe sepsis and septic shock – a goal that
appeared insurmountable for many years – is possible. Is this
optimism justified? Actually, the body of data from extensive
studies on morbidity and mortality of sepsis and infection in
intensive care units (ICUs) is growing, and these data are far
from encouraging. Angus and coworkers [4] analyzed more
than 6 million hospital discharge records from seven states in
the USA and estimated that 751,000 cases of severe sepsis
occur annually, with a mortality rate of 28.6% and leading to
average costs per case of US$22,100. Another, international
study conducted by Alberti and colleagues [5] examined
14,364 patients in six European countries, Canada and
Israel, with more than 4500 documented infectious episodes
either on ICU admission or during prolonged hospital stay.
The authors found the combination of an infection at the time
of ICU admission and subsequent hospital-acquired
infections to be associated with a particularly devastating
outcome, ranging from a crude hospital mortality rate of
16.9% for noninfected patients to 53.6% for patients who
had repeated courses of infection while in the ICU [5].
Indeed, these data provide little reason for optimism.
Nevertheless, the question remains as to whether the end of
the road is in sight, for epidemiological purposes at least, or
whether further studies will bring important new information.
In 2002, the European Society of Intensive Care Medicine
launched a survey on the incidence of sepsis and septic
shock based on infection, inflammatory response and organ
dysfunction in ICU patients (the Sepsis Occurrence in the
Acutely Ill Patients [SOAP] study) [6]. Moreover, it addressed
various aetiologic, diagnostic, therapeutic and prognostic
issues in this population. This cohort, multicentre,
observational study was performed in May 2002. A total of
3147 patients (62% male, mean age 61±17 years) from
198 ICUs in 24 countries were prospectively enrolled and
followed until death, hospital discharge or up to 60 days.
Preliminary statistics from the SOAP study reveal that there
are large differences in diagnostic and therapeutic standards
between the different countries as well as between ICUs in a
particular country. Occurrence of sepsis ranged from 17.5%
to 72.5% and ICU mortality (for all enrolled patients) from
7.9% to 34.8%. The incidence of early cardiovascular failure
and the widely ranging strategies employed for mechanical
ventilation make it clear that recently evaluated strategies,
namely early goal-directed therapy to stabilize
haemodynamics [2] and use of low tidal volumes in
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Abstract
The encouraging results of recent clinical trials on therapy of severe sepsis and septic shock are
paralleled by ongoing studies on the epidemiology of sepsis and infection in intensive care unit patients
all over the world. The development of network-based systems for assessing morbidity and mortality in
intensive care unit patients has contributed to a significant improvement in quality of care. Data from the
SOAP (Sepsis Occurrence in the Acutely Ill Patient) study demonstrate that the treatment of septic
patients varies widely, and that even those strategies that have been evaluated are not yet implemented
in routine practice. Hence, activities on surveillance and education still merit further attention.
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mechanical ventilation [7], are not yet routinely applied by
intensivists.
Are these facts surprising? We already have many studies
with many documented aspects of the epidemiology of
sepsis. We already know that the composite picture they
provide remains incomplete and emphasizes the
heterogeneity of patients [8]. It is well known that compliance
with new, evaluated strategies is a major problem in intensive
care medicine, and that further education and quality
assurance activities are crucial. It has been demonstrated
that merely the participation of intensivists in clinical trials
that were designed to measure the compliance of ICU
physicians with guidelines before and after a defined time
period was able to improve the quality of care [9]. Are
multicentre studies such as SOAP able to improve the quality
of intensive care treatment, and do we need more of them?
We are convinced that this is the case. New developments in
network-based registries of septic patients will progressively
lead to better assessment of risk factors and individual
therapeutic management. Participation in such registries will
increase awareness of acute symptoms and predisposing
conditions. Finally, the data reveal changes over time, and it
is essential that these temporal trends are documented [8].
Even as large a database as that from SOAP or similar studies
is only a small fraction of the important research conducted in
this area. Recent advances in unravelling the pathophysiology
and genetic basis for the host response to sepsis have
already improved our understanding of sepsis [10].
Approaches to new concepts are expected [11], which raises
the question of whether new epidemiological data lead to new
implications for clinical trials in sepsis. Brun-Buisson [12] has
pointed out that criteria for systemic inflammatory response
syndrome and sepsis are not nearly specific enough, and that
selection of patients for inclusion into trials, stratification of
data on inclusion, and end-points and efficacy analyses based
on further aspects of comorbidities and risk factors will be
necessary to reduce the ‘background noise’. Finally, a crucial
aspect for the near future will be economic evaluation. Novel
therapies can no longer be judged simply by their
effectiveness in treating illness, but must also be evaluated on
an institutional and societal level on the basis of their cost
[13]. Hence, future studies on the epidemiology of sepsis and
septic shock will have to implement aspects of costs and the
use of resources such as time, space and personnel.
In conclusion, recent data from epidemiological studies on
sepsis and septic shock revealed highly interesting and
important information, but are no reason to relax. Further data
acquisition will be necessary if we are to improve research
into new therapeutic approaches and the economics of
sepsis treatment. Finally, epidemiology is not only a way to
gain further data; it is also a very effective educational tool for
both investigators and study participants. So, let’s go on and
learn more!
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